News
-
-
PRESS RELEASE
Nuclear Medicine Specialist Ken Herrmann Joins Supervisory Board of Pentixapharm Holding AG
Nuclear Medicine Specialist Ken Herrmann joins Pentixapharm Holding AG's Supervisory Board, bringing expertise in radiopharmaceuticals and theranostics. His appointment aims to advance oncology pipeline -
-
-
-
PRESS RELEASE
Pentixapharm’s CXCR4 Core Compound Subject of 17 Abstract Presentations at the Hamburg European Association of Nuclear Medicine (EANM)
Pentixapharm presents CXCR4 targeting compounds in 17 abstracts at EANM Congress, showcasing theranostic developments and research initiatives in various medical areas -
-
PRESS RELEASE
EQS-Adhoc: EMA Grants PRIME Status to Pentixapharm’s Lead Candidate PentixaFor
EMA grants PRIME status to Pentixapharm’s lead candidate Ga68-PentixaFor, offering early and proactive support for radiodiagnostic development in primary aldosteronism. PentixaFor aims to transform diagnostic subtyping with non-invasive PET imaging targeting CXCR4 -
-